Vertex

Vertex Pharmaceuticals Incorporated, founded in 1989, is a leading biotechnology company focused on developing and commercializing medicines for serious diseases with significant unmet medical needs. Its portfolio includes therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. Vertex leverages its expertise in small-molecule drug discovery to create transformative treatments. With a global presence, Vertex serves patients worldwide through healthcare providers, specialty pharmacies, hospitals, and distributors. Learn about Vertex's global headquarters in Boston, Massachusetts, for details on its operational footprint. The company's scientific advancement is driven by its dedicated workforce; learn more about the individuals shaping its future by visiting Meet Vertex's team.

Vertex's research extends to kidney disease, type 1 diabetes, myotonic dystrophy, and other genetic disorders, aiming to address a wide spectrum of challenging health conditions. Operating with 5,000-10,000 employees across 12 locations, Vertex maintains a significant operational scale. Its strategic focus on precision medicine and genetic therapies positions it at the forefront of pharmaceutical innovation, with a core mission to deliver life-changing treatments.

Financially, Vertex reported substantial revenue, demonstrating its market strength. In the fiscal year ending December 31, 2023, the company generated $12.2 billion in revenue. This performance supports ongoing R&D and expansion into new therapeutic areas. Vertex operates within a competitive landscape, facing established pharmaceutical and biotechnology firms. Further insights into its financial standing, including funding history and performance metrics, are available via Explore financial highlights.